Does how long mTOR is inhibited decide which complex is inhibited — and how are mTORC1 and mTORC2 coupled in time?

Framing gap · evidence stands at: Lifespan in mice · Atlas ID F7

The gap

Rapamycin is called an mTORC1 drug, and at first it is. Given for longer, it also starts to take apart the second complex, mTORC2, in many cell types, and in mice that is linked to the drug's effect on blood sugar. So how long the drug stays on may decide which of the two complexes it hits. The two complexes also talk to each other through feedback, so switching one off changes the other with a delay. Almost all the work on mTOR timing looks at mTORC1 alone.

Technical framing: Rapamycin is usually described as an mTORC1 inhibitor, and acutely it is. With prolonged exposure it also blocks assembly of new mTORC2 in many cell types and reduces AKT signalling (SAR2006), and in mice chronic rapamycin impairs glucose homeostasis through mTORC2 disruption (LAM2012). The duration of exposure, not only the dose, therefore decides which complex is affected. The two complexes are also coupled through feedback: S6K1 downstream of mTORC1 dampens insulin signalling upstream of mTORC2, so blocking mTORC1 can first raise AKT activity before longer exposure lowers it. Most work on mTOR dynamics is about mTORC1; the time course of mTORC2 and of this coupling is rarely measured.

What changed

Alternative regimens given every few days or weekly spared glucose tolerance and the immune system that daily dosing impaired, while still inhibiting mTORC1 (ARR2015), and intermittent dosing extends lifespan in female C57BL/6J mice (Arriola Apelo, J Gerontol A 2016, PMID 27091134). Human trials now sample over time after a dose: RAP PAC draws blood out to 168 hours after a weekly dose (NCT05949658), and RESTOR compares daily with intermittent dosing (NCT06658093). They will measure the time course of inhibition, though not necessarily of each complex separately.

What is still open

How quickly mTORC2 falls and recovers in tissues under weekly against daily dosing in vivo, how much this differs between tissues, and whether the early rise in AKT signalling after mTORC1 inhibition matters for the outcomes measured. Whether mTORC2 activity has its own dynamics, such as pulses or a daily rhythm, that carry information is largely unexplored.

How it could be tested

In mice on daily against intermittent rapamycin at a matched weekly dose, sample liver, muscle and fat at several times after dosing. Read mTORC1 substrates (S6, 4E-BP1) and mTORC2 substrates (AKT S473, the SGK1 target NDRG1) together with mTORC2 assembly by Rictor co-immunoprecipitation. The prediction is a lag: mTORC2 loss appears only after a threshold exposure time and recovers between intermittent doses. No lag, or no recovery, would weaken the timing explanation for why intermittent dosing is better tolerated.

Why it matters

It would turn the mTORC2-sparing argument for intermittent dosing from a plausible rationale into a measured time course, and it brings the second complex into a question that has so far been asked almost only about mTORC1.

Evidence behind this question

Gap not yet confirmed by a logged literature search. The text states that the comparison was not found, but the literature search behind that statement is not logged. (checked 2026-10-15)

How it relates to the other frontier questions: Separate from F1, F4 and F6: it concerns which complex is inhibited as exposure lengthens, not the decoding of pulse patterns.

Direct evidence for a premise

• Sarbassov et al. 2006 (SAR2006) — Prolonged rapamycin treatment blocks assembly of new mTORC2 and reduces Akt signalling in many cell types.
• Lamming et al. 2012 (LAM2012) — Chronic rapamycin impairs glucose homeostasis in mice through mTORC2 disruption.

Related evidence

• Arriola Apelo et al. 2015 (ARR2015) — Regimens given every few days or weekly spared glucose tolerance and the immune system that daily dosing impaired, while still inhibiting mTORC1.
• Arriola Apelo et al. 2016 (ARR2016) — Intermittent rapamycin dosing extended lifespan in female C57BL/6J mice.
• RAP PAC (NCT05949658) (registered trial, not in the Atlas corpus) — Human trial that draws blood out to 168 hours after a weekly dose. Registered; no results cited.
• RESTOR (NCT06658093) (registered trial, not in the Atlas corpus) — Human trial comparing daily with intermittent dosing. Registered; no results cited.

Assumption not yet verified

• S6K1 feedback on insulin signalling — The text says blocking mTORC1 can first raise AKT activity through relief of S6K1 feedback. No citation is given yet.

The grouping is the curator's reading of how each paper is used here. It has not been checked by a second reader.

Bears on these open questions

• Does mTORC1-selective dosing extend lifespan, and is rapamycin's glucose intolerance a cost at all?
• Muscle-sparing, pulsed mTORC1 inhibition

← All frontier questions · Open questions